saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

[1]  Annie Shen,et al.  Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection , 2022, Nature Communications.

[2]  J. Lieberman,et al.  FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation , 2022, Nature.

[3]  E. Settembre,et al.  Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models , 2022, Molecular Therapy - Methods & Clinical Development.

[4]  J. Mascola,et al.  mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron , 2022, Cell.

[5]  Irena Vlatkovic,et al.  COVID-19 mRNA vaccines: Platforms and current developments , 2022, Molecular Therapy.

[6]  N. Pantazis,et al.  Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination , 2022, Vaccines.

[7]  Tiffany F. Chen,et al.  A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models , 2022, Molecular Therapy.

[8]  S. McCormack,et al.  Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial , 2021, eClinicalMedicine.

[9]  E. Moriishi,et al.  OMIP 075: A 22‐color panel for the measurement of antigen‐specific T‐cell responses in human and nonhuman primates , 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  S. Kishigami,et al.  SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity , 2021, Nature Communications.

[11]  J. Wise.  Covid-19: The E484K mutation and the risks it poses , 2021, BMJ.

[12]  P. McKay,et al.  Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice , 2021, Nature Communications.

[13]  D. Ho,et al.  Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes , 2020, Cell Reports.

[14]  M. Beltramello,et al.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.

[15]  H. Feldmann,et al.  An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates , 2020, Science Translational Medicine.

[16]  Jie Zhou,et al.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.

[17]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[18]  Fumihiro Kato,et al.  Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.

[19]  J. J. Skehel,et al.  Influenza hemagglutinin membrane anchor , 2018, Proceedings of the National Academy of Sciences.

[20]  D. Weissman,et al.  Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses , 2018, The Journal of experimental medicine.

[21]  Yun Zhang,et al.  Recombinant influenza H9N2 virus with a substitution of H3 hemagglutinin transmembrane domain showed enhanced immunogenicity in mice and chicken , 2017, Scientific Reports.

[22]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  T. Schlake,et al.  Developing mRNA-vaccine technologies , 2012, RNA biology.

[24]  D. G. Gibson,et al.  Enzymatic assembly of DNA molecules up to several hundred kilobases , 2009, Nature Methods.

[25]  R. Johnston,et al.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. , 1997, Virology.

[26]  S. Pierce,et al.  Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. , 1988, Journal of immunology.

[27]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .